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N-Acetylglucosaminyltransferase IThe HIV-1 envelope glycoprotein complex (Env) is the focus of vaccine development aimed at eliciting
humoral immunity. Env's extensive and heterogeneous N-linked glycosylation affects folding, binding to
lectin receptors, antigenicity and immunogenicity. We characterized recombinant Env proteins and virus
particles produced in mammalian cells that lack N-acetylglucosaminyltransferase I (GnTI), an enzyme
necessary for the conversion of oligomannose N-glycans to complex N-glycans. Carbohydrate analyses
revealed that trimeric Env produced in GnTI−/− cells contained exclusively oligomannose N-glycans, with
incompletely trimmed oligomannose glycans predominating. The folding and conformation of Env proteins
was little affected by the manipulation of the glycosylation. Viruses produced in GnTI−/− cells were
infectious, indicating that the conversion to complex glycans is not necessary for Env entry function,
although virus binding to the C-type lectin DC-SIGN was enhanced. Manipulating Env's N-glycosylation may
be useful for structural and functional studies and for vaccine design.tal Virology, Department of
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The entry of human immunodeﬁciency virus type 1 (HIV-1) into
target cells is mediated by the envelope glycoprotein (Env) complex,
which consists of three gp120/gp41 heterodimers. The Env complex is
located on the virion surface and is the target for virus-neutralizing
antibodies (NAbs) that are generated by infected individuals. The
protein components of the Env complex are, therefore, the focus of all
HIV-1 vaccine strategies intended to induce NAbs. Such approaches
most commonly involve the use of individual gp120 surface
glycoproteins or gp41 transmembrane glycoproteins, fragments of
these proteins, or mimetics of the Env complex created by expressing
gp140 trimers containing both gp120 and the gp41 ectodomain.
Half the molecular mass of gp120 is comprised of N-linked glycans
that overlie the protein backbone, and the gp41 ectodomain is also
glycosylated, although to a lesser extent. Env glycosylation is im-
portant at several stages in the viral life cycle. First, N-glycans play anessential role in the oxidative folding of gp120 in the endoplasmic
reticulum (ER); inhibiting glycosylation impairs the production of
functional Env proteins (Walker et al., 1987). Second, N-glycans form
the binding sites for ancillary receptors such as DC-SIGN and langerin
that are involved in the binding of HIV-1 to, e.g., dendritic cells (DC),
and that facilitate or impede its subsequent transmission to T cells (de
Witte et al., 2007; Geijtenbeek et al., 2000; Lin et al., 2003; Marzi et al.,
2007). Third, the poorly immunogenic N-glycans play a critical role in
HIV-1 immune evasion, by shielding underlying NAb epitopes on the
gp120 and gp41 protein backbones (Reitter et al., 1998). Themannose
moieties on gp120 N-glycans can also induce immunosuppressive
cytokine responses under certain conditions (Banerjee et al., 2009;
Shan et al., 2007). Although mannose moieties on N-linked glycans
constitute the epitope for 2G12, one of the very few relatively broadly
active NAbs (Calarese et al., 2005, 2003; Sanders et al., 2002a; Scanlan
et al., 2002; Trkola et al., 1995), the extensive glycosylation of gp120 is
a hindrance to the use of Env proteins as vaccine antigens.
The extent, heterogeneity and ﬂexibility of Env glycosylation also
interfere with the formation of protein crystals, which seriously
compromises attempts to determinemolecular structures. Indeed, the
structures of gp120 core fragments could not be obtained without
enzymatic deglycosylation of the proteins to facilitate crystallization
(Huang et al., 2007, 2005; Kwong et al., 1998; Zhou et al., 2007). A
237D. Eggink et al. / Virology 401 (2010) 236–247better understanding of Env glycosylation is therefore likely to help
both vaccine and structural studies, particularly ones involving
recombinant Env trimers.
We have been studying and reﬁning a recombinant trimer
construct, SOSIP gp140, that is stabilized by an intermolecular disulﬁde
bond between gp120 and gp41 and a point substitution in gp41
(Binley et al., 2000; Sanders et al., 2002b). The SOSIP gp140 trimers are
proteolytically cleaved at the gp120–gp41 junction, a process that
alters their antigenicity and immunogenicity and thatmaymake them
better mimics of the native Env complex, compared with uncleaved
trimers (Binley et al., 2000; Dey et al., 2009; Pancera et al., 2005; Si
et al., 2003). We now wish to be able to modify the glycan content of
SOSIP gp140 trimers for the reasons outlined above. As a ﬁrst step, we
have assessedwhether Envmonomers and trimers can be produced in
a cell line (293S GnTI−/−) that has been engineered to prevent the
production of complex type N-glycans, leaving oligomannose glycans
as the only Env glycan component (Reeves et al., 2002).Fig. 1. Study design. (A) Schematic of the gp120 and gp140 proteins used in this study. Constr
and blue, respectively. KNH1144 gp120 was modiﬁed to reconstitute the epitope for D7324
gp140 and KNH1144 SOSIP.R6MPER gp140 contain several modiﬁcations that have mostly b
disulﬁde bond (Binley et al., 2000); the I559P substitution to promote trimerization (San
trimerization (Harbury et al., 1994; Yang et al., 2000a,b) followed by anD7324 epitope tag; the
substitutions, A662E, G664D, N668S and T671N (indicated in red) to introduce the 2F5 and 4E
gp120 and gp140 proteins produced inwild typemammalian cells are designated as oligoman
1990). It is assumed that the glycans present at analogous sites are processed similarly on the
some sites depends on the study and isolate used (Cutalo et al., 2004; Leonard et al., 1990; Zhu
occupied by both complex and oligomannose sugars (Cutalo et al., 2004; Zhu et al., 2000). Site
as being of unknown glycan composition. The glycans on gp41 have not been characterized. (
GnTI−/− cells and in 293T cells treated with kifunensine indicated. The cellular sites at whicResults
Expression of recombinant HIV-1 Env glycoproteins in mammalian cells
lacking N-acetylglucosaminyltransferase I
The various Env proteins used in this study are depicted
schematically in Fig. 1A. Our strategy to reduce the extent and
heterogeneity of Env glycosylation involved expressing monomeric
gp120 and trimeric gp140 proteins in 293S GnTI−/− cells that do not
express UDP-N-acetylglucosamine:α-D-mannoside-β1,2-N-acetylglu-
cosaminyltransferase I (GlcNAc transferase I; GnTI) (Reeves et al.,
2002). The absence of this enzyme prevents the attachment of GlcNAc
to Man5GlcNAc2 glycans in the medial-Golgi; as a result, complex
carbohydrate chains of variable composition are not formed. Hence,
glycoproteins produced in 293S GnTI−/− cells are expected to contain
predominantly oligomannosidic N-glycans with 5 mannose residues
(Fig. 1B) (Chang et al., 2007; Reeves et al., 2002).ucts based on the sequences from LAI, JR-FL and KNH1144 are indicated in orange, green
in the C5 domain (substitutions: R500K, R502K and G507Q). JR-FL SOSIP.R6-IZ-D7324
een described elsewhere, including the A501C and T605C substitutions to create the SOS
ders et al., 2002b); the GCN4-based isoleucine zipper (IZ) introduction to promote
hexa-arginine (R6) cleavage site to enhance cleavage (Binley et al., 2002); and theMPER
10 epitopes into KNH1144 SOSIP.R6 gp140 (Dey et al., 2009). TheN-linked glycan sites on
nose or complex, based on experimental determinations using IIIB gp120 (Leonard et al.,
other gp120s, but we note that theN-glycan type (oligomannose vs. complex) present at
et al., 2000). Furthermore, some sites can be occupied in only a subset ofmolecules, or be
s that are present on LAI, JR-FL or KNH1144 gp120, but not on IIIB gp120, are designated
B) Schematic of themammalian N-linked glycosylation pathwaywith the blocks in 293S
h processing occur are also indicated.
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293S GnTI−/− cells and, for comparison, in wild type 293T cells that
do express GnTI. The gp120s were derived from isolates LAI, JR-FL
(both subtype B) and KNH1144 (subtype A). The KNH1144 gp120 had
a minor modiﬁcation from the original sequence; the C5 domain
epitope for Ab D7324 was optimized to facilitate analyses by antigen–
capture ELISA (Fig. 1A). All three gp120s were expressed efﬁciently in
the 293S GnTI−/− cells (Fig. 2A). The 293S GnTI−/− cell-derived
gp120s migrated more rapidly in SDS-PAGE gels than the
corresponding proteins from 293T cells; their lower apparent
molecular weight (∼110 kDa compared to ∼120 kDa) is consistent
with a decrease in glycan size as a result of the blocked conversion of
Man5GlcNAc2 moieties to complex glycans. We note that sialylation of
complex N-glycans produced in 293T cells may inﬂuence their
migration in SDS-PAGE and the ∼10 kDa size difference may be a
slight underestimation of the absolute size difference.
We next investigated whether different forms of gp140 trimers
based on the JR-FL or KNH1144 sequences could be expressed
efﬁciently in 293S GnTI−/− cells. The JR-FL SOSIP.R6-IZ-D7324
gp140 construct contains several modiﬁcations, including a heterol-
ogous trimerization domain based onGCN4 at its C-terminus (Harbury
et al., 1994; Yang et al., 2000a,b) and aD7324-epitope tag (Fig. 1A). The
addition of the GCN4 domain increases SOSIP gp140 trimer formation
and/or stability, but interferes with cleavage at the gp120–gp41
juncture. From here on, we will refer to this construct as uncleaved
JR-FL gp140. When this protein was expressed in either 293T or 293S
GnTI−/− cells, it formed trimers efﬁciently, although they were not
cleaved (Fig. 2B, and data not shown).
Trimeric SOSIP gp140 proteins (without C-terminal additions) are
substantially (N90%) cleaved when produced in mammalian cells in
the presence of co-transfected furin (Sanders et al., 2002b). KNH1144
SOSIP gp140s are particularly useful for structural studies because
they form trimers more efﬁciently than the corresponding proteins
derived from various other strains such as JR-FL (Beddows et al.,Fig. 2. Expression of gp120 and gp140 in 293T cells and in 293S cells lacking the GnTI enzyme
or 293S GnTI−/− cells. (B) SDS-PAGE and BN-PAGE analysis of uncleaved JR-FL SOSIP.R6-IZ-D
KNH1144 SOSIP.R6 MPER gp140 expressed in the presence of furin, in either 293T cells wit
analysis of uncleaved JR-FL SOSIP.R6-IZ gp140 trimers produced in 293T or 293S GnTI−/– c
analyzed by SDS-PAGE and western blot. The peak fractions of the standard protein thyrogl2006). Because KNH1144 Env proteins do not bind MAbs 2F5 and
4E10 due to sequence variation, we introduced these epitopes by
mutagenesis, to create KNH1144 SOSIP.R6 MPER gp140 (Fig. 1A) (Dey
et al., 2009). From here on, we refer to this construct as cleaved
KNH1144 gp140. When this protein was expressed in 293S GnTI−/−
cells in the presence of furin, it formed trimers efﬁciently (Fig. 2C).
Moreover, these trimers were fully cleaved, as judged by their
conversion to monomeric gp120s on reducing SDS-PAGE gels (Fig. 2C
and data not shown). As observed when monomeric gp120 proteins
were produced in 293S GnTI−/− cells (Fig. 2A), the gp120 component
of the gp140 trimers migrated with an apparent molecular weight of
∼110 kDa, slightly less than the ∼120 kDa proteins expressed in 293T
cells (Fig. 2C).
To further characterize the oligomeric states of gp140 trimers
produced in 293T and 293S GnTI−/− cells, we performed analytical
size exclusion chromatography using a Superose-6 column. Concen-
trated supernatant from the Env-transfected cell cultures were
column-fractionated and then analyzed by SDS-PAGE and western
blot. The uncleaved JR-FL gp140 and the cleaved KNH1144 gp140
proteins, whether produced in 293T or 293S GnTI−/− cells, were
eluted in fractions between the peaks for ferritin (440 kDa) and
thyroglobulin (669 kDa) (Fig. 2D and data not shown). These
observations are consistent with our earlier ﬁndings (Sanders et al.,
2002b), and imply that Env proteins produced in 293S GnTI−/− cells
form trimers efﬁciently.
Expression of SOSIP gp140 trimers in the presence of kifunensine
Kifunensine is a mannose analog that inhibits both type I
mannosidases in the endoplasmic reticulum and α-mannosidases in
the Golgi, resulting in the production of glycoproteins that contain
predominantly Man9GlcNAc2 carbohydrates (Elbein et al., 1990).
Thus, by preventing the trimming of these moieties to Man5GlcNAc2,
kifunensine inhibits an earlier step in the carbohydrate-processing. (A) SDS-PAGE analysis of LAI, JR-FL and KNH1144 gp120s expressed transiently in 293T
7324 gp140, expressed in both cell types. (C) SDS-PAGE and BN-PAGE analysis of cleaved
h or without kifunensine, or in 293S GnTI–/– cells. (D) Size exclusion chromatography
ells and fractionated using a Superose-6 column. The fractions (indicated on top) were
obulin (669 kDa), ferritin (440 kDa) and BSA (67 kDa) are indicated.
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monomeric gp120 can be successfully expressed in 293T cells in the
presence of kifunensine (Scanlan et al., 2007), this approach may be a
useful alternative way to reduce glycan heterogeneity on gp140
trimers. We therefore produced cleaved KNH1144 gp140 trimers in
293T cells in the presence and absence of kifunensine, and in the
presence of furin, then compared themwith trimers produced in 293S
GnTI−/− cells (Fig. 2C). The efﬁciency of trimer production was
independent of kifunensine use. Furthermore, the size of the gp120
components of the trimers was unaffected by kifunensine, whereas
the gp120 moieties produced in 293S GnTI−/− cells were, as noted
above, ∼10 kDa smaller (Fig. 2C). The presence of only oligomannose
glycans was conﬁrmed by EndoH digestion (data not shown).
Env trimers from 293S GnTI−/− cells contain exclusively oligomannosidic
N-glycan species
To establish which N-glycans are present on cleaved KNH1144
trimers produced in 293S GnTI−/−, we ﬁrst released all N-glycans by
PNGase F treatment. Subsequently, the free, reducing end N-
acetylglucosamine residues were reacted with 2-AA to introduce a
ﬂuorescent label. The released, labeled glycan pool was analyzed by
HILIC HPLC with ﬂuorescence detection, and by MALDI-TOF mass
spectrometry. The HILIC HPLC analysis showed that a relatively simple
mixture of N-glycans was present, separated into ﬁve major fractions
(Fig. 3A). The MALDI-TOF mass spectrum (Fig. 3B) also indicated that
ﬁve major glycan species were present. The major LC fractions (3, 5, 7,
8, and 9) were each collected and analyzed by MALDI-TOF MS (Fig. 3,
panels C–G, respectively). The observedm/z values show that a single
glycan species with the composition HexnNAc2-AA was present in
each of these fractions, with n=5 for the glycan in panel C, n=6 in
panel D, n=7 in E, n=8 in F and n=9 in G. These data imply that
Man5GlcNAc2 to Man9GlcNAc2 oligomannosidic glycans are present
on KNH1144 gp140 trimers, withMan5GlcNAc2 (26.9%), Man8GlcNAc2
(24.9%) and Man9GlcNAc2 (28.6%) being the major species (see
Fig. 3A). Thus, N-glycans on trimeric Env are substantially resistant to
mannosidase trimming, which stands in contrast to reports that other
proteins expressed in 293S GnTI−/− cells bear homogenous Man5-
GlcNAc2 glycans (Chang et al., 2007; Reeves et al., 2002), but is
consistent with the presence of oligomannose glycans on Env
produced under natural glycosylation conditions.
Env proteins produced in 293T and 293S GnTI−/− cells are antigenically
similar
To assess whether the antigenic structures of gp120 and gp140
proteins were affected by eliminating complex carbohydrates, we
measured their reactivity with a panel of MAbs against conforma-
tional epitopes. We ﬁrst used the D7324–capture ELISA to study LAI,
JR-FL and KNH1144 gp120s. The 293T and 293S GnTI−/− cell-derived
JR-FL and LAI gp120s bound a CD4 mimetic (CD4–IgG2) and MAb b12
to the CD4 binding site, to similar extents. GnTI−/− cell-derived
gp120s showed enhanced reactivity with pooled Ig from HIV-positive
individuals (HIVIg), suggesting that some unidentiﬁed antibody
epitopes become more accessible when complex N-glycans are
absent. This effect was subtle and was not reproduced with a different
lot of HIVIg (not shown). Conformational changes in all the gp120s
were induced by soluble CD4 (sCD4), as indicated by the increased
binding of MAb 17b to a CD4-induced (CD4i) epitope (Fig. 4A). The
binding of 17b to LAI gp120 from 293S GnTI−/− cells was, however,
slightly decreased compared to its counterpart from 293T cells.Fig. 3. Glycosylation analysis of gp140 trimers produced in the absence of GnTI. (A)HILIC
chromatogram and (B) MALDI-TOF MS spectrum of enzymatically released, 2-AA
labeled N-glycans of KNH1144 trimers from 293S GnTI−/− cells. (C–G) MALDI-TOF MS
spectra of RP-LC fractions 3,5,7,8 and 9, respectively.
Fig. 4. Antigenic properties of gp120 and gp140 proteins that lack complex N-glycans. ELISA analysis of the binding of HIVIg, b12, 17b (in the absence of sCD4: gray lines and symbols;
in the presence of sCD4: black lines and symbols) and CD4–IgG2 to: (A) LAI, JR-FL or KNH1144 gp120 proteins expressed in 293T cells or in 293S GnTI−/− cells; (B) uncleaved JR-FL
SOSIP.R6-IZ-D7324 gp140 expressed in the same two cell types. (C) Immunoprecipitation analysis of cleaved KNH1144 SOSIP.R6 MPER gp140 expressed in 293T cells with furin and
with or without kifunensine, or in 293S GnTI−/− cells. The Env proteins were precipitated with CD4–IgG2, b12 or 2F5, and then analyzed by SDS-PAGE and western blot. (D) ELISA
analysis of the binding of the V3 MAbs 39F, 19b, and PA1 with JR-FL gp120 expressed in 293T or GnTI−/− cells.
240 D. Eggink et al. / Virology 401 (2010) 236–247KNH1144 gp120 interacted efﬁciently with HIVIg, CD4–IgG2 and 17b,
but not with b12, consistent with sequence variation in critical b12
contact residues (P369L, V372T, M373T, P417Q, and E462K) (Pan-
tophlet et al., 2003; Zhou et al., 2007). Again, there was little effect of
the producer cell line on the reactivity of the gp120, except for the
subtly enhanced HIVIg binding. Thus, it appears that monomeric
gp120 folds normally in 293S GnTI−/− cells despite the manipulation
of its glycan structures.
We next evaluated the uncleaved JR-FL gp140 trimers using the
D7324–capture ELISA. There were no marked differences in how CD4–IgG2 orMAbs b12 and 2F5 (to gp41) bound to trimers from 293S GnTI−/
− and 293T cells (Fig. 4B). The binding of HIVIg was enhanced upon
expression in GnTI−/− cells, but the effect was more subtle than
observed with gp120 monomers, suggesting that the (unknown)
epitopes that become more exposed when complex N-glycans are
absent, are affected by trimerization. MAb 17b bound slightly less
efﬁciently to the trimers from the 293S GnTI−/− cells, but its epitope
was strongly induced by sCD4 irrespective of the producer cell type
(Fig. 4B). Most of the gp120-directed MAbs and CD4-based reagents
bound similarly to monomeric and uncleaved, trimeric JR-FL Env with
241D. Eggink et al. / Virology 401 (2010) 236–247the exception of 17b, which interacted less efﬁciently with trimeric
gp140 (compare Fig. 4A middle panels with Fig. 4B).
TheD3724–capture ELISAmethod cannot be used to analyze cleaved
SOSIP gp140 trimers; the internal D7324 epitope is mutated and
occluded, while the epitope tag added to the C-terminus of the gp41
moiety interferes with gp140 cleavage. We therefore used less
quantitative immunoprecipitation assays to study MAb binding to
cleavedKNH1144gp140 trimers that hadbeenproduced in293T cells inFig. 5. Interactions of gp120 and gp140 proteins lacking complex N-glycans with 2G12 and DC
commonly found onproteins expressed in293SGnTI−/− cells, and in kifunensine-treated293T
involved in 2G12 binding (blue) and DC-SIGN binding (core binding site: red; additional conta
et al., 2007; Feinberg et al., 2001; Guo et al., 2004; Scanlan et al., 2002; van Liempt et al., 2006). (B)
cells. (C) Binding of 2G12 and DC-SIGN to uncleaved JR-FL SOSIP.R6-IZ-D7324 gp140 trimers. (
D7324 gp140 by mannan or EGTA. (E) Binding of cleaved KNH1144 SOSIP.R6 MPER gp140 tothe presence or absence of kifunensine, or in 293S GnTI−/− cells
(Fig. 4C). Irrespective of how they were produced, the trimers reacted
efﬁciently with CD4–IgG2 andMAbs 17b and 2F5. As was seen with the
corresponding gp120, b12 boundpoorly to theKNH1144 gp140 trimers.
We tested the reactivity of three V3 MAbs with JR-FL gp120
(Fig. 4D) and trimers (not shown) expressed in 293T or 293S GnTI−/−
cells (PA1 (Trkola et al., 1996a), 39F (Pantophlet et al., 2008), and 19b
(Pantophlet et al., 2008); Fig. 4D), but we did not observe signiﬁcant-SIGN. (A) Chemical structures of Man5GlcNAc2 (left) and Man9GlcNAc2 (right) N-glycans
cells, respectively (Elbein et al., 1990; Reeves et al., 2002). The individualmannoses that are
cts: burgundy and blue) are indicated (Calarese et al., 2005; Calarese et al., 2003; Feinberg
Binding of 2G12 and DC-SIGN to three different gp120s produced in 293T or 293S GnTI−/−
D) Inhibition of DC-SIGN binding to LAI, JR-FL and KNH1144 gp120 and JR-FL SOSIP.R6-IZ-
2G12 and DC-SIGN, analyzed by immunoprecipitation.
242 D. Eggink et al. / Virology 401 (2010) 236–247differences in V3 MAb binding to recombinant monomers and
(uncleaved) trimers. These results are in contrast with ﬁndings on
complete virus, which becomesmore sensitive to neutralization by V3
MAbs when produced in GnTI−/− cells (James Binley and RWS,
unpublished observations). In addition, the V3 can become more
accessible and more sensitive to proteolytic cleavage upon desialyla-
tion (Papandreou and Fenouillet, 1998). Combined these and our
observations conﬁrm that differences exist between virus-associated
Env and recombinant Env monomers and uncleaved trimers.
Reactivity of 2G12 and DC-SIGN with glycan-modiﬁed Env proteins
MAb 2G12 binds to gp120 via the terminal α1–2-linked mannoses
on the outer branches of a cluster of oligomannose carbohydrates
(Fig. 5A) (Calarese et al., 2005, 2003; Sanders et al., 2002a; Scanlan
et al., 2002; Trkola et al., 1995). We therefore studied 2G12 reactivity
with gp120 proteins expressed under the various conditions described
above. MAb 2G12 bound efﬁciently to 293T cell-derived LAI and JR-FL
gp120s but poorly to KNH1144 gp120, which lacks the glycan at
residue 295 that is an important element of the 2G12 epitope (Fig. 5B)
(Sanders et al., 2002a; Scanlan et al., 2002; Trkola et al., 1995). MAb
2G12 bound equallywell to the LAI and JR-FL gp120s produced in 293S
GnTI−/− cells (Fig. 5B). Thus, production of gp120 in GnTI−/− cells
preserves the 2G12 epitope. It is therefore likely that the untrimmed
and/or incompletely trimmedMan6–9GlcNAc2 glycans that retainα1–
2-linkedmannoses (Fig. 3) include the ones involved in 2G12 binding.
DC-SIGN also binds to gp120 via a cluster of exposed mannose
moieties (Fig. 5A) (Hong et al., 2007; Lin et al., 2003; Shan et al., 2007).
The speciﬁcity of DC-SIGN binding is less well deﬁned than that of
2G12, but there appears to be some overlap between the two binding
sites (Binley et al., 2006; Hong et al., 2007). DC-SIGN bound strongly
to 293T cell-expressed LAI and JR-FL gp120s, but reacted poorly withFig. 6. Virus produced in 293S GnTI−/− cells is infectious and can be captured efﬁciently by
293S GnTI−/− cells. Equal amounts of the various virus stocks (1 ng of CA-p24 antigen) wer
293T and 293S GnTI−/− cells by Raji–DC-SIGN cells. (C) Transmission of GnTI−/− produced
and 293S GnTI−/− cells by DC. (E) Transmission of GnTI−/− produced virus from DC to TZKNH1144 gp120 (Fig. 6A). All three gp120s from 293S GnTI−/− cells
interacted more strongly with DC-SIGN than the same proteins
produced in 293T cells (Fig. 5B).
We next compared how 2G12 and DC-SIGN bound to JR-FL gp120
monomers and uncleaved JR-FL gp140 trimers in the D7324–capture
ELISA. The reactivity patterns were similar for the two types of Env
protein. Thus, as was seen with JR-FL gp120 monomers, 2G12 bound
with similar apparent afﬁnity to gp140 trimers produced in 293T and
293S GnTI−/− cells, whereas DC-SIGN reacted better with the trimers
from 293S GnTI−/− cells (Fig. 5C). Mannan and EGTA were able to
block the binding of DC-SIGN to gp120 and trimeric gp140 proteins
from both cell types (Fig. 5D).
We used immunoprecipitationmethods to study 2G12 and DC-SIGN
binding to cleaved KNH1144 gp140 trimers. CD4 bound similarly to
trimers produced in 293T cells (+/− kifunensine) and in 293SGnTI−/−
cells, again showing that the trimers were properly folded (Fig. 5E).
As was observed using the corresponding gp120 in ELISA, DC-SIGN
bound poorly to cleaved KNH1144 gp140 trimers, irrespective of the
producer cells (Figs. 5B and E). Even though 2G12 bound only weakly
to KNH1144 gp140 (which lacks a relevant glycan at position 295),
the binding was moderately increased when the trimers were
produced in the presence of kifunensine (Fig. 5B). As previously
proposed the explanation may be that additional binding sites for
2G12 are created (Scanlan et al., 2007).
HIV-1 produced in 293S GnTI−/− cells is infectious and efﬁciently
captured by DC-SIGN expressing cells
As a more rigorous test of whether the presence of only
oligomannose glycans affected Env function, we produced HIV-1 LAI
and JR-CSF viruses in 293S GnTI−/− cells and in 293T cells, by
transfection under comparable conditions. For both viruses, the type ofDC-SIGN expressing cells. (A) Infectivity of LAI and JR-CSF virus produced in 293T and
e used to infect TZM-bl reporter cells. (B) Capture of LAI and JR-CSF viruses produced in
virus from Raji–DC-SIGN cells. (D) Capture of LAI and JR-CSF viruses produced in 293T
M-bl reporter cells. * represents Pb0.05; ** Pb0.005 and *** Pb0.0005.
243D. Eggink et al. / Virology 401 (2010) 236–247producer cell did not have an inﬂuence on infectivity in a reporter cell
assay (Fig. 6A). These results conﬁrm that the absence of complex
carbohydrates has no adverse effects on Env entry function (Fenouillet
et al., 1996).
Because we observed an increase in DC-SIGN binding to Env
proteins derived from 293S GnTI−/− cells, we investigated whether
viruses from these cells would be captured more efﬁciently by DC-
SIGN-expressing cells. HIV-1 LAI and JR-FL viruses derived from 293T
cells and 293S GnTI−/− cells were therefore incubated with Raji
control cells or Raji–DC-SIGN cells, and virus capturewas quantiﬁed by
p24 antigen ELISA. HIV-1 did not bind detectably to Raji cells, whereas
Raji–DC-SIGN cells captured viruses very efﬁciently (Fig. 6B). More-
over, viruses produced in 293S GnTI−/− cells were captured to a
greater extent than ones from293T cells. Immaturemonocyte-derived
dendritic cells (iMDDC) also captured HIV-1 efﬁciently in a mannan-
sensitivemanner, conﬁrming the involvement of C-type lectins such as
DC-SIGN (Fig. 6D). Again, viruses from 293S GnTI−/−cells were more
reactive with iMDDC than their counterparts from 293T cells. One
exception was the binding of HIV-1 LAI to iMDDC. Thus, HIV-1 LAI
produced in 293S GnTI−/−cells consistently interacted less efﬁciently
with iMDDC compared to the same virus derived from 293T cells
(Fig. 6D). It is therefore possible that other receptors than DC-SIGN,
possibly ones with afﬁnity for complex glycans, contribute to the
binding of HIV-1 LAI, but not HIV-1 JR-CSF, to iMDDC.
We next measured the transmission of DC-SIGN-bound HIV-1 to
TZM-bl target cells. Although LAI and JR-CSF viruses from293SGnTI−/−
cells bound more efﬁciently to Raji–DC-SIGN, they were less able to
infect TZM-bl cells in co-culture systems than their counterparts from
293T cells (Figs. 6B and C). A similar trendwas observed for capture and
transmission of JR-CSF by iMDDCs. LAI virus produced in GnTI−/− cells,
however, did not bindmore efﬁciently to iMDDCs, suggesting that other
C-type lectin receptors than DC-SIGN play a role in capture of LAI virus
by iMDDCs.Nevertheless, the data suggest that the altered glycosylation
proﬁle that promotes the binding of virions to cell surface DC-SIGN
impairs their subsequent transmission to target cells.
Discussion
Reducing the size and heterogeneity of the N-linked glycans that
shield the underlying peptide epitopes on the HIV-1 Env glycoproteins
could be beneﬁcial for the use of these proteins in structural and
immunogenicity studies. Here, we have studied the properties of
various monomeric gp120 and trimeric gp140 proteins that were
produced in 293SGnTI−/− cells, variants of 293T cells that lack the GnTI
enzymeandhence cannot synthesize complexN-glycans (Fig. 1B). As an
alternative approach, we expressed the same Env glycoproteins in 293T
cells, but in thepresenceof an inhibitor, kifunensine, that interfereswith
an earlier stage in the glycan-processing pathway (Fig. 1B). Importantly,
the elimination of complex N-glycans did not compromise Env
conformation and/or entry function, in agreement with previous
studies using the mannosidase inhibitors 1-deoxynojirimycin and
swainsonine (Monteﬁori et al., 1988; Pal et al., 1989).
Glycoproteins produced when kifunensine is present have been
reported to contain predominantlyMan9GlcNAc2N-glycans (Chang et al.,
2007; Elbein et al., 1990), while those produced in 293S GnTI−/−cells
bearmostlyMan5GlcNAc2N-glycans, the substrates for the knocked-out
GnTI gene (Chang et al., 2007; Reeves et al., 2002). In contrast to
the ﬁndings obtained with other proteins (Chang et al., 2007; Reeves
et al., 2002), we observed considerable amounts of incompletely
trimmed Man6–9GlcNAc2 glycans on GnTI−/− produced Env trimers. A
number of Env N-glycans must be resistant to mannosidase activity in
the ER and/or Golgi. This is of course consistent with the presence of
both oligomannose and complex N-glycans on Env proteins produced
under normal conditions (e.g., in wild type cells or the absence of an
inhibitor). Nevertheless, Env trimers with smaller and more homoge-
nous N-glycans can be produced in 293S GnTI−/− cells. Of note is thatGnTI knock-out variants of Chinese hamster ovary (CHO) cells have also
been described (Lec1 and Lec3.2.8.1) (Fenouillet et al., 1996; Stanley,
1993). Such lines may also be suitable for producing recombinant Env
trimers with homogeneous oligomannose glycans.
An alternative way to generate Env trimers containing only
oligomannose glycans would be to express them in insect cells,
which cannot generate complex glycans. Indeed, all the gp120s for
which X-ray crystallography structures have been obtained from such
cells (Huang et al., 2007, 2005; Kwong et al., 1998; Zhou et al., 2007).
We have attempted to express SOSIP gp140 trimers in insect cells
using the baculovirus system, but gp120–gp41 cleavage is very
inefﬁcient evenwhen human furin is co-delivered (RWS, Giel Bosman,
Wim de Grip, unpublished results).
Both gp120 monomers and gp140 trimers from three different
HIV-1 strains (JR-FL, LAI and KNH1144) were expressed efﬁciently in
293S GnTI−/− cells, and in kifunensine-treated 293T cells; under both
circumstances, trimerization and cleavage of the gp140s, when
appropriate, occurred normally. The glycan-modiﬁed Env proteins
all interacted efﬁciently with HIVIg, CD4–IgG2 and various MAbs to
conformational epitopes on gp120 and gp41. Hence the absence of
complex glycans did not detectably affect the correct folding of these
Env glycoproteins. Moreover, viruses produced in GnTI−/− cells were
infectious, conﬁrming that Env entry function was not affected.
Kifunensine did not affect the size of Env proteins, in contrast to
observations that others have made about other proteins, where
kifunensine reduces both the size and heterogeneity of glycans (Scanlan
et al., 2007). Hence, the average size of the complex carbohydrates on
Env is no larger than the Man9GlcNAc2 structure, which is consistent
with the observation that relatively simple diantennary complex
glycans predominate on gp120 (MW, DE, RWS and CHH, unpublished
observations and (Cutalo et al., 2004; Mizuochi et al., 1988; Zhu et al.,
2000)). In contrast, Env proteins from 293S GnTI−/− cells were slightly
smaller, which is consistent with mannosidase trimming of most of the
Man9GlcNAc2 structures. The complete trimming of ∼24 glycans to
Man5GlcNAc2 would reduce the gp120 m.wt. by ∼17 kDa (i.e., 4
mannose residues of ∼0.18 kDa removed from ∼24 glycans). The
observed sizedifference (∼10 kDa; Fig. 2) therefore already implied that
mannose trimming was incomplete. A more direct analysis then
conﬁrmed that a large proportion of Env glycans was indeed of the
Man6–9GlcNAc2 forms (Fig. 3). Thus, expressing Env in 293S GnTI−/−
cells effectively results in the conversion of complex carbohydrates to
Man5GlcNAc2 moieties, but does not change the composition of any
oligomannose carbohydrates that are resistant to mannose trimming;
those glycans remain as Man6–9GlcNAc2 structures.
We analyzed the interaction of Env proteins with two carbohy-
drate-binding proteins that bind to oligomannose glycans: MAb 2G12
and the C-type lectin receptor DC-SIGN. These ligands are known to
have different but overlapping speciﬁcities and requirements for
oligomannose glycans. The 2G12 MAb binds to a cluster of
oligomannose carbohydrates containing α1–2-linked terminal man-
noses (Calarese et al., 2005, 2003; Sanders et al., 2002a; Scanlan et al.,
2002) (Fig. 5A). Env proteins from 293S GnTI−/− cells interacted
efﬁciently with 2G12, which suggests that carbohydrates involved in
2G12 binding (e.g. those attached to residues 295, 332 and 392, and
possibly 386 and 448) are resistant to mannosidase activity in the ER
and/or Golgi, and hence retain their α1–2-linked terminal mannoses.
DC-SIGN bound strongly to 293T cell-expressed LAI and JR-FL
gp120s, but not to KNH1144 gp120. This observation is consistent
with our ﬁnding that KNH1144 gp120 could not induce IL-10 from DC
via an interaction with mannose C-type lectin receptors, whereas LAI
and JR-FL gp120s could do so (Shan et al., 2007). The limited binding
of DC-SIGN to KNH1144 gp120may, as for 2G12, be attributable to the
absence of the glycan at residue 295 that is involved in the binding of
both ligands (Hong et al., 2007; Sanders et al., 2002a; Scanlan et al.,
2002; Trkola et al., 1996b). Alternatively, or as well, the carbohydrate
at position 160, which is present on gp120s from LAI and JR-FL but not
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DC-SIGN binding (Borggren et al., 2008; Lue et al., 2002).
We found that Env proteins and viruses from 293S GnTI−/− cells
consistently bound DC-SIGN more strongly than their counterparts
from 293T cells. DC-SIGN interacts with the outer tri-mannose core on
Man5–9GlcNAc2 sugars, but α1–2-linked mannose moieties that are
absent from Man5GlcNAc2 structures provide additional contacts
(Feinberg et al., 2007, 2001; Guo et al., 2004; van Liempt et al., 2006).
We suggest that the natural DC-SIGN binding site(s) on oligomannose
Man6–9GlcNAc2 sugars is unaltered on gp120 moieties produced in
293S GnTI−/− cells, but that the replacement of complex glycans by
Man5GlcNAc2 carbohydrates creates additional binding sites for DC-
SIGN. These extra sites would probably be of lower afﬁnity because
they lack α1–2-linked mannoses.
Of note is that enhancing HIV-1 binding to DC-SIGN actually
decreased its subsequent transmission fromDCs to target cells (Fig. 6).
An explanation is that too strong an interaction with DC-SIGN may
prevent the virus from dissociating at a time and place necessary for
the captured virion to reroute to virological synapses that form upon
encounter of a DC with a target T cell, instead of being targeted for
degradation. Thus, there may be a delicate balance between the
requirements for association of virus with DC-SIGN and subsequent
steps in the transmission process.
In summary, we have produced well-folded gp120 monomers and
both uncleaved and cleaved gp140 trimers bearing glycan structures
that are smaller and more homogeneous than is normally the case.
These glycan-modiﬁed proteins may be useful for immunogenicity
and structural studies.
Materials and methods
Plasmids
The pPPI4 vector system for expressing gp120 and gp140 proteins
has been described elsewhere (Binley et al., 2000). Single amino acid
substitutions were made using the Quickchange mutagenesis kit
(Stratagene, La Jolla, CA). The various Env proteins described below
are all summarized in Fig. 1A.
We modiﬁed the C5 region of KNH1144 gp120 to introduce the
epitope for the polyclonal sheep anti-gp120 antibody (Ab) D7324 and
thereby facilitate analysis of ligand binding to gp120 in a D7324–
capture ELISA; the KNH1144 sequence APTRARRRVVGREKR was
altered to APTKAKRRVVQREKR. We modiﬁed the JR-FL SOSIP.R6
gp140 construct to include a C-terminal GCN4-based trimerization
domain (isoleucine zipper; IZ) and the above D7324 epitope tag,
linked by ﬂexible spacers, to create the JR-FL SOSIP.R6-IZ-D7324
gp140 protein. Note that the internal D7324 epitope in the C5 domain
of SOSIP constructs is mutated by the introduction of the cysteine at
residue 501 that forms the intramolecular disulﬁde bond with gp41,
and it is also occluded by the proximity of the gp41 subunit; hence
unmodiﬁed SOSIP gp140s do not react efﬁciently with Ab D7324
(Binley et al., 2000; Sanders et al., 2002b). Because of the addition of
C-terminal sequences to SOSIP gp140, SOSIP.R6-IZ-D7324 trimers are
uncleaved. A more detailed description of the SOSIP.R6-IZ-tag and
related constructs will be published elsewhere.
The KNH1144 SOSIP.R6 MPER gp140 construct containing engi-
neered epitopes forMAbs 2F5 and 4E10 has been described previously
(Dey et al., 2009). Note that the gp140 used here does not contain the
S295N change that enhances binding by 2G12 (Dey et al., 2009).
Reagents
DC-SIGN-Fc was purchased from R&D Systems (Minneapolis, MN).
HIVIg was obtained through the AIDS Research and Reference Reagent
Program (ARRRP), Division of AIDS, NIAID, NIH. MAbs 2G12 and 2F5
were obtained from Hermann Katinger through the ARRRP. MAb b12was donated by Dennis Burton (The Scripps Research Institute, La
Jolla, CA). MAbs 17b and 39F were gifts from James Robinson (Tulane
University, New Orleans, LA). The CD4–IgG2 and sCD4 proteins have
been described elsewhere (Allaway et al., 1995).D7324 monomer and trimer ELISA
Enzyme-linked immunosorbent assays (ELISA) were performed as
described previously (Shan et al., 2007), with minor modiﬁcations.
Microlon 96-well plates (Greiner Bio-One, Alphen aan den Rijn, The
Netherlands) were coated overnight with Ab D7324 (Aalto Biorea-
gents, Dublin, Ireland) at 10 µg/ml in 0.1 M NaHCO3, pH 8.6 (100 µl/
well). Subsequently, gp120 or SOSIP.R6-IZ-D7324 gp140 (diluted in
TBS/10% fetal bovine serum (FBS)) was captured by the coated D7324
for 2 h before addition of TSM/5% BSA to block protein-binding sites
on the well surface (TSM; 20 mM Tris, 150 mM NaCl, 1.0 mM CaCl2,
2.0 mM MgCl2). Serially diluted HIVIg, MAbs, DC-SIGN-Fc or CD4–
IgG2 in TSM/5% BSA was then added for 2 h followed by 3 washes
with TSM/0.05% Tween-20. Horseradish peroxidase (HRP)-labeled
goat-anti-human immunoglobulin G (IgG) (Jackson Immunoresearch,
Suffolk, England) was added for 30 min at a 1:5000 dilution (ﬁnal
concentration 0.2 µg/ml) in TSM/5% BSA, followed by 5 washes with
TSM/0.05% Tween-20. DC-SIGN blocking experiments were per-
formed using 1 µg/ml DC-SIGN in the presence of 300 µg/ml mannan
or 10 mM EGTA. Colorimetric detection was performed using a
solution containing 1% 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma-
Aldrich, Zwijndrecht, The Netherlands), 0.01% H2O2 in 0.1 M sodium
acetate, and 0.1 M citric acid. The colorimetric reaction was stopped
using 0.8 M H2SO4 when appropriate, and absorption was measured
at 450 nm.SDS-PAGE, Blue Native PAGE and western blotting
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western
blotting were performed according to established protocols using the
anti-gp120 V3 loop MAb PA-1 (1:5,000 dilution to a ﬁnal concentra-
tion of 0.2 µg/ml) (Trkola et al., 1996a) and HRP-labeled goat-anti-
mouse IgG (1:5000 dilution). Luminometric detection of envelope
glycoproteins was performed using theWestern Lightning ECL system
(PerkinElmer, Groningen, The Netherlands). Blue Native (BN)-PAGE
was carried out using minor modiﬁcations to the published method
(Schagger et al., 1994; Schagger and von Jagow, 1991; Schulke et al.,
2002). Thus, puriﬁed protein samples or cell culture supernatants
were diluted with an equal volume of a buffer containing 100 mM 4-
(N-morpholino) propane sulfonic acid (MOPS), 100 mM Tris–HCl, pH
7.7, 40% glycerol, and 0.1% Coomassie blue, immediately prior to
loading onto a 4 to 12% Bis-Tris NuPAGE gel (Invitrogen). Typically, gel
electrophoresis was performed for 2 h at 150 V (∼0.07A) using
50 mM MOPS, 50 mM Tris, pH 7.7 as running buffer.Immunoprecipitation assays
Twenty-fold concentrated supernatants from transiently Env-
transfected 293T or 293S GnTI–/− cells were incubated overnight at
4 °C with MAbs or CD4–IgG2 in a 500 µl volume that contained 100 µl
of 5-fold concentrated RIPA buffer (250 mM Tris–HCl, pH 7.0 contain-
ing 750 mM NaCl and 5 mM EDTA). Next, 50 µl of protein G-coated
agarose beads (Pierce Inc./Thermo Fisher Scientiﬁc, Etten-Leur, The
Netherlands) was added, with rotation-mixing, for 2 h at 4 °C. The
beads were then washed extensively with ice-cold RIPA buffer
containing 0.01% Tween-20. Proteins were eluted by heating the
beads at 100 °C for 5 min in 50 µl of SDS-PAGE loading buffer
supplemented with 100 mM dithiothreitol (DTT). The immunopreci-
pitates were analyzed on 8% SDS-PAGE gels (125 V for 2 h).
245D. Eggink et al. / Virology 401 (2010) 236–247Analytical size exclusion chromatography
Twenty-fold concentrated, Env-containing supernatants (200 µl)
from 293T or 293S GnT− cell cultures were fractionated using a
Superose-6 10/300 GL column (GE Healthcare, Diegem, The
Netherlands), equilibrated with phosphate buffered saline, using an
Äkta FPLC system (GE Healthcare, Diegem, The Netherlands).
Fractions were analyzed by SDS-PAGE and western blot.
Carbohydrate analysis
Puriﬁed KNH1144 gp140 trimers (620 ng in 10 µl) produced in
293S GnTI−/− cells were denatured by addition of 20 µl of 2% SDS and
heating at 60 °C for 10 min. Subsequently, 10 µl of 4% NP-40 and 10 µl
of PNGase F (0.5 mU) in 5× PBS were added to the samples (ﬁnal:
0.1 mU PNGase F in 0.8% NP-40, 0.4% SDS, 1× PBS), which were
then incubated overnight at 37 °C to allow N-glycan release. The
releasedN-glycanswere subsequently labeledwith the ﬂuorophore 2-
aminobenzoic acid (2-AA), and the 2-AA labeled glycanswere puriﬁed
by solid-phase extraction as described elsewhere (Ruhaak et al.,
2008).
An aliquot of 2-AA labeled N-glycans was fractionated by
hydrophilic interaction liquid chromatography (HILIC HPLC), using
an Ultimate LC system (Dionex, Sunnyvale, CA) controlled by
Chromeleon software and equipped with a 2.0 mm×150 mm TSK
gel-Amide 80 column (3 µm; Tosoh Biosciences, Stuttgart, Germany).
The 2-AA labeled N-glycans were separated using a linear gradient
from 80% acetonitrile (0 min) to 53% acetonitrile (40 min) in 50 mM
ammonium formate (pH 4.4) at a ﬂow rate of 0.3 ml/min. To identify
the 2-AA labeled N-glycans, a ﬂuorescence detector (FP-2020 plus;
Jasco, Easton, MD) was used, set to a 360 nm excitation wavelength
and a 420 nm emission wavelength. Peak fractions were collected,
dried by vacuum centrifugation, and dissolved in 50 µl of water.
MALDI-TOF-MS was carried out on an Ultraﬂex II MALDI-TOF/TOF
mass spectrometer (Bruker Daltonics), equipped with a Smartbeam
laser. A 2 µl aliquot of 2,5-dihydroxybenzoic acid (DHB) matrix
(20 mg/ml in ACN:water (30:70 v/v)) and 1 µl of the test sample
were applied to a polished steel target plate and left to dry. The
Ultraﬂexwas operated in reﬂector-negativemode, and calibrationwas
performed on a peptide calibration standard (Bruker Daltonics). Mass
spectra from 500 to 2000 laser shots were accumulated per sample.
Cell culture and transient transfection
The TZM-bl reporter cell line stably expresses high levels of CD4
and the CCR5 and CXCR4 coreceptors, and contains the luciferase and
β-galactosidase genes under the control of the HIV-1 LTR promoter
(Wei et al., 2002). These cells were obtained through the ARRRP
(donated by Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.,
Durham, NC). One day prior to infection, the cells were plated on a 96-
well plate in DMEM containing 10% FBS, MEM nonessential amino
acids and penicillin/streptomycin (both at 100 U/ml).
The 293T and 293S GnTI−/− cells were transiently transfected
with env genes using linear polyethylenimine (PEI, MW 25,000) as
described before (Kirschner et al., 2006). Brieﬂy, DNA encoding Env
protein was diluted in Dulbecco's Modiﬁed Eagle's Medium (DMEM;
Invitrogen, Breda, The Netherlands), to 1/10 of the ﬁnal culture
volume and mixed with PEI (0.15 mg/ml ﬁnal concentration). After
incubation for 20 min, the DNA–PEI mix was added to the cells for 4 h
before replacement with normal culture medium containing 10% FBS
(HyClone, Perbio, Etten-Leur, The Netherlands), penicillin, strepto-
mycin andMEMnonessential amino acids (0.1 mM, Invitrogen, Breda,
The Netherlands). Supernatants were harvested 48 h after transfec-
tion. When appropriate, 100 µM kifunensine was added 1 h before
transfection, and the culture medium was replaced 4 h post
transfection with medium containing 100 µM kifunensine.The Raji control cell line and Raji cells expressing DC-SIGN (Raji–
DC-SIGN) were cultured in RPMI 1640 medium containing 10% FBS.
DC-SIGN expression by Raji–DC-SIGN cells was positively selected for
using neomycin (2 µg/ml), and routinely monitored by FACS analysis
with a PE-labeled DC-SIGNMAb. Human immaturemonocyte-derived
dendritic cells (iMDDCs) were prepared as previously described
(Sallusto and Lanzavecchia, 1994; van Montfort et al., 2007, 2008)
Brieﬂy, peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats (Central Laboratory Blood Bank, Amsterdam) by use
of a Ficoll gradient and positive CD14 selection using a MACS system
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Puriﬁed
monocytes were differentiated into iMDDCs by adding 45 ng/ml of
interleukin-4 (IL-4) and 500 U/ml of granulocyte–macrophage
colony-stimulating factor on days 1 and 4 (Schering-Plough, Brussels,
Belgium). The resulting iMMDCs were used on day 6. The phenotype
of iMDDCs was conﬁrmed by staining for MHC class II, CD1a, CD14,
CD83 and CD86, followed by ﬂow cytometry. Low levels of CD83,
CD86 and MHC class II proteins were present on the cell surface,
indicative of an immature phenotype.
Virus infectivity
HIV-1 stocks were prepared by transfecting either 293T or 293S
GnTI−/− cells as for recombinant protein production (see above). A
ﬁxed amount of virus (equivalent to 1.0 ng p24 antigen) was added to
TZM-bl cells (at 70–80% conﬂuency in a 96-well plate) in the presence
of 400 nM saquinavir (Roche, Basel, Switzerland) to prevent multiple
rounds of infection, and 40 µg/ml DEAE-dextran (Sigma) to enhance
infection, in a total volume of 200 µl. Themediumwas removed 2 days
post-infection and the cells were washed once with PBS before lysis
with Reporter Lysis Buffer (Promega, Madison,WI). Luciferase activity
was measured using the Luciferase Assay kit (Promega) and a Glomax
luminometer, according to the manufacturer's instructions (Turner
BioSystems, Sunnyvale, CA). All infections were performed in
duplicate and luciferase measurements were also performed in
duplicate. Background luciferase activity was determined using
uninfected cells and used as a correction factor.
Virus capture and transmission
Either 1.0×106 Raji or Raji–DC-SIGN cells, or 3.0×105 iMDDCs
treatedwith orwithoutmannan (30 µg/ml) for 30 min,were incubated
for 2 hwith HIV-1 (15 ng/ml of p24 antigen) that had been produced in
either 293T or 293S GnTI−/− cells. The cells were washed 3 times with
PBS to remove unbound virus, and then lysed in 1% empigen detergent
for 1 h at 56 °C. Cell-debris was removed by centrifugation and the p24
capsid antigen content of the supernatantwas determined by ELISA. For
transmission experiments, 1.0×105 Raji or Raji–DC-SIGN cells, or
iMDDCs (with or without mannan treatment), were incubated for 2 h
with HIV-1 (3 ng/ml of p24 antigen) derived from either 293T or 293S
GnTI−/− cells. Unbound virus was removed by washing the cells three
times with RPMI 1640 medium supplemented with 10% heat-
inactivated FBS. The cells were co-cultured with TZM-bl reporter cells
for 48 h in presence of 400 nMsaquinavir. HIV-1 transfer to the reporter
cells was quantiﬁed by measuring luciferase activity.
Statistical analysis
All statistical comparisons were performed using the unpaired
t test (two tailed) and indicated in ﬁgures with asterisks: * Pb0.05;
** Pb0.005; *** Pb0.0005.
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